Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY450139 versus placebo for progression of Alzheimer's disease
2008-002758-39Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing LY450139 with Placebo (2 arms). Primary endpoints: Change from baseline to endpoint in ADAS-Cog11 and Change from baseline to endpoint in ADCS-ADL. Started Jul 2008; status: completed.
02
Drugs
semagacestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2008-002758-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002758-39.